Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution.

Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided ...

Celestica has delivered strong revenue and EPS growth, driven by AI and cloud infrastructure demand. Click here to read why ...

Researchers developed a method to measure how efficiently lipid nanoparticles release genetic cargo within mice, overcoming a longstanding hurdle in gene therapy.